Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +75

Eli Lilly and Company (LLY) Stock: Surges 4.50% as Foundayo Delivers Positive Phase 3 Sleep Apnea Results

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ LLY stock jumped 4.50% to $1,414.93 on Monday following the release of positive Phase 3 clinical results for Foundayo.

🩺 The ATTAIN-OSA program met its primary endpoint by significantly reducing the apnea-hypopnea index in adults with moderate-to-severe obstructive sleep apnea.

βš–οΈ Foundayo reduced sleep apnea events by 43.8% among participants without PAP therapy and 27.5% among those using PAP therapy after 52 weeks.

πŸ“‰ The treatment delivered average weight reductions of 11.5% for patients without PAP therapy and 11.2% for those with PAP therapy.

πŸ₯ Participants showed improvements in systolic blood pressure and inflammatory markers, addressing key cardiovascular risk factors associated with obesity.

πŸ—“οΈ Eli Lilly plans to submit an application for FDA approval for Foundayo's sleep apnea indication by December 2026.

πŸ“Š Findings were presented at the American Heart Association Scientific Sessions 2026 and published in the journal JAMA.

⚠️ Gastrointestinal symptoms such as nausea, diarrhea, and vomiting were identified as the most common adverse events during the trials.

πŸ“‰ Discontinuation rates due to adverse events were 12.2% for non-PAP users and 6.8% for PAP users receiving Foundayo versus placebo.

πŸ’Ό The positive results support Eli Lilly's strategy to expand its cardiometabolic portfolio beyond current obesity treatments like Zepbound.

Bullish Signals
  • LLY stock rallied 4.50% to $1,414.93 driven by positive Phase 3 data showing Foundayo met its primary endpoint for reducing sleep apnea severity.
  • The drug reduced sleep apnea events by 43.8% in non-PAP users and 27.5% in PAP users, validating efficacy across different treatment populations.
  • Foundayo delivered average weight loss exceeding 11% across both patient groups, reinforcing its dual benefit for obesity and sleep apnea management.
  • Clinical trials demonstrated improvements in systolic blood pressure and inflammatory markers, expanding the drug's potential cardiometabolic value proposition.
  • Eli Lilly plans an FDA submission by December 2026 to expand Foundayo's approved indications, creating a new revenue stream within its portfolio.
Risk Factors
  • Gastrointestinal adverse events including nausea, diarrhea, and vomiting were common, leading to a 12.2% discontinuation rate among non-PAP users.
  • Discontinuation rates due to side effects reached 6.8% for patients using PAP therapy, compared to lower rates observed with placebo.
Full Analysis
Eli Lilly and Company (LLY) shares surged 4.50% to $1,414.93 following the announcement of positive Phase 3 clinical results for its investigational drug Foundayo (orforglipron). The ATTAIN-OSA program evaluated the treatment in adults with moderate-to-severe obstructive sleep apnea and obesity, demonstrating significant efficacy in reducing breathing interruptions and supporting weight loss. The study met its primary endpoint by significantly lowering the apnea-hypopnea index after 52 weeks. Among participants not using positive airway pressure (PAP) therapy, Foundayo reduced sleep apnea events by 43.8%, while those using PAP therapy saw a 27.5% decline. Additionally, the treatment delivered average weight reductions exceeding 11% across both patient groups, alongside improvements in systolic blood pressure and inflammatory markers. Eli Lilly plans to submit an application for FDA approval for Foundayo's use in obstructive sleep apnea by December 2026. The company presented findings at the American Heart Association Scientific Sessions 2026 and published them in JAMA, aiming to expand its cardiometabolic portfolio beyond existing obesity treatments like Zepbound. While gastrointestinal side effects were noted, the positive clinical data strengthens Lilly's position in treating obesity-related health conditions.